JPRN-UMIN000009716招募中1 期
Phase I trial of eribulin/S-1 combination therapy for advanced/recurrent breast cancer pretreated by anthracycline and taxane - Phase I trial of eribulin/S-1 combination therapy for advanced/recurrent breast cancer pretreated by anthracycline and taxane
Depertment of medical oncology, Kinki University Hospital, Faculty of medicine0 个研究点目标入组 12 人开始时间: 2013年1月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •(1) with symptoms of infectious disease (2) pleural effusion, peritoneal effusion which needs drainage (3) brain metastasis with the necessity of treatment (4) patients with following serious complication 1) Ischemic heart disease and arrhythmic cardiac disease with poor control. 2) ischemic heart disease within 6 months, 3) liver cirrhosis, 4) watery diarrhea 5) interstitial pneumonia or pulmonary fibrosis by chest radiograph 6) bleeding tendency 7) another serious complication (5) patients who need to receive continuous corticosteroid administration (6) positive for HBs antigen (7) patients who treated by widespread radiation therapy (8) pregnant or nursing women (9) patients who are participating in the other clinical trial (10) patients who judged improper to entry this trial by physician
研究者
相似试验
已完成
2 期
Phase 2 trial of eribulin/S-1 combination therapy for advanced/recurrent breast cancerAdvanced and recurrent breast cancerJPRN-UMIN000015049Advanced Clinical Research Organization32
已完成
2 期
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who presented well-defined taxane resistanceBreast CancerJPRN-UMIN000006965Saitama Breast Cancer Clinical Study Group (SBCCSG)52
已完成
不适用
Phase II clinical trial of the combination of eribulin and trastuzumab for advanced/recurrent HER2-positive breast cancer: observational studybreast cancerJPRN-UMIN000028594Dept. of Endocrine & Breast Surgery, Kyoto Prefectural University of Medicine30
已完成
2 期
Phase II clinical trial of the combination of eribulin and trastuzumab for advanced/recurrent HER2-positive breast cancerAdvanced/recurrent HER2-positive breast cancerJPRN-UMIN000009890Kyoto Prefectural University of Medicine30
招募中
不适用
A study to evaluatethe safety and efficacy of eribulin in combination with gemcitabine in previously treated patients with advanced Liposarcoma or Leimyosarcoma.NeoplasmsKCT0003547Yonsei University Health System, Severance Hospital37